Compare Dr. Reddys with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs STRIDES PHARMA SCIENCE - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB STRIDES PHARMA SCIENCE DR. REDDYS LAB/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 40.5 18.5 218.4% View Chart
P/BV x 5.5 1.1 481.6% View Chart
Dividend Yield % 0.4 0.4 101.0%  

Financials

 DR. REDDYS LAB   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
DR. REDDYS LAB/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2,8751,147 250.7%   
Low Rs1,888642 294.1%   
Sales per share (Unadj.) Rs930.2317.2 293.2%  
Earnings per share (Unadj.) Rs117.47.8 1,496.8%  
Cash flow per share (Unadj.) Rs185.825.1 741.4%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.2 375.6%  
Book value per share (Unadj.) Rs844.4274.3 307.9%  
Shares outstanding (eoy) m166.0789.50 185.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.8 90.8%   
Avg P/E ratio x20.3114.0 17.8%  
P/CF ratio (eoy) x12.835.7 35.9%  
Price / Book Value ratio x2.83.3 86.5%  
Dividend payout %17.025.5 66.8%   
Avg Mkt Cap Rs m395,49680,058 494.0%   
No. of employees `00022.02.5 876.2%   
Total wages/salary Rs m33,5624,341 773.2%   
Avg. sales/employee Rs Th7,032.811,325.8 62.1%   
Avg. wages/employee Rs Th1,527.91,731.4 88.2%   
Avg. net profit/employee Rs Th887.7280.1 317.0%   
INCOME DATA
Net Sales Rs m154,48228,394 544.1%  
Other income Rs m3,375941 358.8%   
Total revenues Rs m157,85729,334 538.1%   
Gross profit Rs m31,7823,965 801.5%  
Depreciation Rs m11,3481,540 736.7%   
Interest Rs m8891,962 45.3%   
Profit before tax Rs m22,9201,403 1,633.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m438-168 -260.7%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m3,85897 3,965.1%   
Profit after tax Rs m19,500702 2,777.4%  
Gross profit margin %20.614.0 147.3%  
Effective tax rate %16.86.9 242.7%   
Net profit margin %12.62.5 510.5%  
BALANCE SHEET DATA
Current assets Rs m111,10124,836 447.3%   
Current liabilities Rs m58,97318,993 310.5%   
Net working cap to sales %33.720.6 164.0%  
Current ratio x1.91.3 144.1%  
Inventory Days Days7971 111.8%  
Debtors Days Days94113 83.1%  
Net fixed assets Rs m101,24534,289 295.3%   
Share capital Rs m830895 92.7%   
"Free" reserves Rs m139,40623,651 589.4%   
Net worth Rs m140,23624,546 571.3%   
Long term debt Rs m22,00015,513 141.8%   
Total assets Rs m224,65665,437 343.3%  
Interest coverage x26.81.7 1,561.6%   
Debt to equity ratio x0.20.6 24.8%  
Sales to assets ratio x0.70.4 158.5%   
Return on assets %9.14.1 222.9%  
Return on equity %13.92.9 486.1%  
Return on capital %14.96.9 216.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67315,697 564.9%   
Fx outflow Rs m19,104735 2,597.8%   
Net fx Rs m69,56914,962 465.0%   
CASH FLOW
From Operations Rs m28,7041,871 1,534.4%  
From Investments Rs m-7,7275,826 -132.6%  
From Financial Activity Rs m-21,326-10,157 210.0%  
Net Cashflow Rs m-314-2,615 12.0%  

Share Holding

Indian Promoters % 25.5 27.7 92.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 37.8 14.3%  
FIIs % 35.3 8.6 410.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 25.9 59.1%  
Shareholders   75,885 56,241 134.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   TORRENT PHARMA  ALKEM LABORATORIES  ELDER PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 748 Points Higher; Energy and Finance Stocks Rally(Closing)

Indian share markets continued their momentum and ended on a strong note today. The three-day Monetary Policy Committee meeting kicked off today.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Why the Stock of HDFC Bank Deserves a Closer Look than Before...(Profit Hunter)

Jul 22, 2020

HDFC Bank's results point to a gaping hole in Indian financial sector. Possibly even a global contagion.

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

My Best Trading Ideas When Interest Rates Are So Low(Fast Profits Daily)

Jul 23, 2020

India's interest rates are lower than the inflation rate. Here are the best trades for this situation.

Gold or Silver: Which One Should You Buy Now?(Fast Profits Daily)

Jul 24, 2020

Silver and gold are both vying for your attention. Which is the better trade today?

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 4, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS